The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy.
Ana Gómez RuedaÁlvaro TausRosa Álvarez ÁlvarezReyes Bernabé-CaroLuis CharaMarta López-BreaLaia VilàMaria Ángeles Sala GonzálezAnabel Del Barrio Díaz AldagalánBeatriz Esteban HerreraRafael López CastroRuth Álvarez CabellosMarta DoménechSandra FalaganAlberto Moreno VegaCarlos AguadoAndrés BarbaMaria Teresa Delgado UreñaDolores IslaLorena Bellido HernándezJosé Luis Fírvida PérezÓscar Juan-VidalBartomeu MassutíXabier Mielgo-RubioAna Laura OrtegaSilvia CatotManuel DómineCorina Escoín-PérezFrancisco García NavalónIgnacio Gil-BazoSilvia MuñozDelvys Rodríguez-AbreuRosa María Villatoro RoldánGuillermo Alonso-Jáudenes CurberaLuis León-MateosAiram PadillaAlfredo Paredes LarioJosé Miguel Sánchez-TorresPilar Garrido Lopeznull nullPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2024)
These results are in line with prior published evidence and confirm the benefits of durvalumab in the treatment of LA-NSCLC patients in a real-world setting. We also observed a lower incidence of important treatment-associated toxicities, such as pneumonitis, compared with the pivotal phase III PACIFIC clinical study.
Keyphrases
- phase iii
- small cell lung cancer
- end stage renal disease
- clinical trial
- ejection fraction
- chronic kidney disease
- locally advanced
- risk factors
- peritoneal dialysis
- squamous cell carcinoma
- rectal cancer
- double blind
- electronic health record
- machine learning
- systematic review
- interstitial lung disease
- replacement therapy
- big data
- phase ii
- patient reported
- tyrosine kinase